Arnold & Porter beefs up pharmaceutical group
Arnold & Porter adds Daniel Kracov as partner and co-head of the pharmaceutical and medical device group and Kathleen Means as the group's non-lawyer senior policy advisor. Kracov and Means both hail from Patton Boggs; Kracov was the leader of Patton Boggs' FDA group. Means is a former Senate Finance Committee health advisor and House Ways & Means Committee staffer. She also worked in the senior executive service at the Centers for Medicare & Medicaid Services (1"The Pink Sheet" June 14, 2004, p. 25)...
You may also be interested in...
Congress will move to strike down the Medicare Rx law's "non-interference" provision in the next two years, former Senate Finance Committee health advisor Kathleen Means said at the Biotechnology Industry Organization's annual conference in San Francisco June 9
India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral progress multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.
“Regardless of whether the adulterated products are sold on store shelves, online to consumers, or in bulk format to businesses and other organizations, FDA’s priority is safety," says American Cleaning Institute VP James Kim.